C WorldWide Group Holding A S Makes New $3.59 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

C WorldWide Group Holding A S acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the first quarter, HoldingsChannel.com reports. The fund acquired 95,000 shares of the company’s stock, valued at approximately $3,587,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wells Fargo & Company MN lifted its stake in shares of Vaxcyte by 53.7% during the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company’s stock worth $5,916,000 after purchasing an additional 25,257 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Vaxcyte by 5.5% during the first quarter. Rhumbline Advisers now owns 181,230 shares of the company’s stock worth $6,843,000 after purchasing an additional 9,416 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of Vaxcyte by 203.6% during the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock worth $61,000 after purchasing an additional 1,071 shares in the last quarter. Pictet Asset Management Holding SA lifted its stake in shares of Vaxcyte by 30.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,017,845 shares of the company’s stock worth $83,321,000 after purchasing an additional 236,940 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Vaxcyte by 37.3% in the fourth quarter. Russell Investments Group Ltd. now owns 108,389 shares of the company’s stock worth $8,873,000 after acquiring an additional 29,442 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on PCVX. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Cantor Fitzgerald started coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an “overweight” rating on the stock. Bank of America cut their price objective on Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. The Goldman Sachs Group cut their price objective on Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Finally, Evercore ISI upgraded Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Vaxcyte presently has a consensus rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded down $0.47 during mid-day trading on Friday, reaching $36.90. The company had a trading volume of 97,418 shares, compared to its average volume of 1,487,831. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The stock has a market capitalization of $4.76 billion, a PE ratio of -9.26 and a beta of 1.19. The stock’s 50 day moving average is $33.74 and its 200-day moving average is $54.16.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the business earned ($0.85) EPS. On average, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.